董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Timothy A. Springer | 男 | Director | 71 | 8.00万美元 | 未持股 | 2019-06-27 |
| Vikas Goyal | 男 | Director | 40 | 未披露 | 未持股 | 2019-06-27 |
| Otello Stampacchia | 男 | Director | 50 | 未披露 | 未持股 | 2019-06-27 |
| Nilesh Kumar | 男 | Director | 43 | 未披露 | 未持股 | 2019-06-27 |
| Barbara J. Dalton | -- | Director | 65 | 未披露 | 未持股 | 2019-06-27 |
| Praveen P. Tipirneni | 男 | President, Chief Executive Officer and Director | 50 | 231.71万美元 | 未持股 | 2019-06-27 |
| Norbert Bischofberger | 男 | Director | 63 | 未披露 | 未持股 | 2019-06-27 |
| Gustav Christensen | 男 | Chairman of the Board, Director | 71 | 4.00万美元 | 未持股 | 2019-06-27 |
| Joseph P. Slattery | 男 | Director | 54 | 未披露 | 未持股 | 2019-06-27 |
| Amir Nashat | 男 | Director | 46 | 未披露 | 未持股 | 2019-06-27 |
| Barbara J. Dalton | 女 | Director | 65 | 未披露 | 未持股 | 2019-06-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert E. Farrell | 男 | Vice President of Finance and Operations, Treasurer | 53 | 未披露 | 未持股 | 2019-06-27 |
| William D. DeVaul | 男 | General Counsel and Secretary | 48 | 未披露 | 未持股 | 2019-06-27 |
| Bruce N. Rogers | 男 | Chief Scientific Officer | 50 | 122.04万美元 | 未持股 | 2019-06-27 |
| Alexey A. Lugovskoy | 男 | Chief Development Officer | 46 | 97.03万美元 | 未持股 | 2019-06-27 |
| Praveen P. Tipirneni | 男 | President, Chief Executive Officer and Director | 50 | 231.71万美元 | 未持股 | 2019-06-27 |
董事简历
中英对照 | 中文 | 英文- Timothy A. Springer
-
TimothyA.Springer自2016年6月起担任我们的董事会成员，自2008年12月起担任我们的科学顾问。自1989年以来，Springer博士担任哈佛医学院（Harvard Medical School）的Latham Family教授。他也曾担任Boston Children&8217；s Hospital的细胞和分子医学项目的高级研究员（2012年以来），以及Harvard Medical School的生物化学和分子药理学教授，以及Boston Children&8217；s Hospital的医学教授（2011年以来）。Springer博士是Leukosite的创始人，这是一家1999年被Millennium Pharmaceuticals收购的生物技术公司。此外，他是Scholar Rock and Morphic Therapeutic的创始人、投资者和董事会成员。Springer博士是美国国家科学院（National Academy of Sciences）的成员，他的荣誉包括Crafoord Prize、美国免疫学家协会功勋职业奖、美国血液学会Stratton奖章和美国心脏协会基础研究奖。Springer博士在加州大学伯克利分校（University of California，Berkeley）获得学士学位，在哈佛大学（Harvard University）获得博士学位。
Timothy A. Springer,has served as the Latham Family Professor at Harvard Medical School. He has also served as Senior Investigator in the Program in Cellular and Molecular Medicine at Boston Children's Hospital since 2012, and as Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Professor of Medicine at Boston Children's Hospital since 2011. Dr. Springer was the Founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. Additionally, he was a founder, investor and board member of Morphic Therapeutic until its acquisition by Eli Lilly & Co. in 2024, and a founder, investor and former director of Scholar Rock, where he served as a director until May 2019. Dr. Springer is currently a founder and director of Tectonic Therapeutic since 2020 and Seismic Therapeutic since 2020. He is a founder and board member of the Institute for Protein Innovation since 2016 and trustee of the Marine Biological Laboratory since 2019 (both non-profit organizations). Dr. Springer is an elected member of the National Academy of Sciences and his honors include the Crafoord Prize, the American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, and the Basic Research Prize from the American Heart Association. Dr. Springer also received the Albert Lasker Basic Medical Research Award in 2022, and the Robert Koch Prize in 2023. Dr. Springer received a B.A. from the University of California, Berkeley, and a Ph.D. from Harvard University. - TimothyA.Springer自2016年6月起担任我们的董事会成员，自2008年12月起担任我们的科学顾问。自1989年以来，Springer博士担任哈佛医学院（Harvard Medical School）的Latham Family教授。他也曾担任Boston Children&8217；s Hospital的细胞和分子医学项目的高级研究员（2012年以来），以及Harvard Medical School的生物化学和分子药理学教授，以及Boston Children&8217；s Hospital的医学教授（2011年以来）。Springer博士是Leukosite的创始人，这是一家1999年被Millennium Pharmaceuticals收购的生物技术公司。此外，他是Scholar Rock and Morphic Therapeutic的创始人、投资者和董事会成员。Springer博士是美国国家科学院（National Academy of Sciences）的成员，他的荣誉包括Crafoord Prize、美国免疫学家协会功勋职业奖、美国血液学会Stratton奖章和美国心脏协会基础研究奖。Springer博士在加州大学伯克利分校（University of California，Berkeley）获得学士学位，在哈佛大学（Harvard University）获得博士学位。
- Timothy A. Springer,has served as the Latham Family Professor at Harvard Medical School. He has also served as Senior Investigator in the Program in Cellular and Molecular Medicine at Boston Children's Hospital since 2012, and as Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Professor of Medicine at Boston Children's Hospital since 2011. Dr. Springer was the Founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. Additionally, he was a founder, investor and board member of Morphic Therapeutic until its acquisition by Eli Lilly & Co. in 2024, and a founder, investor and former director of Scholar Rock, where he served as a director until May 2019. Dr. Springer is currently a founder and director of Tectonic Therapeutic since 2020 and Seismic Therapeutic since 2020. He is a founder and board member of the Institute for Protein Innovation since 2016 and trustee of the Marine Biological Laboratory since 2019 (both non-profit organizations). Dr. Springer is an elected member of the National Academy of Sciences and his honors include the Crafoord Prize, the American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, and the Basic Research Prize from the American Heart Association. Dr. Springer also received the Albert Lasker Basic Medical Research Award in 2022, and the Robert Koch Prize in 2023. Dr. Springer received a B.A. from the University of California, Berkeley, and a Ph.D. from Harvard University.
- Vikas Goyal
-
Vikas Goyal自2019年8月以来一直担任我们的高级副总裁，业务开发。在加入我们之前，Goyal先生于2011年至2019年7月担任葛兰素史克公司风险投资部门S.R.One，Limited或S.R.One的负责人。Goyal先生于2018年1月至2019年7月担任我们的董事会成员。Goyal先生是MorphicHolding，Inc.公司（一家公开上市的生物制药公司）董事会成员。Goyal先生在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得医疗保健管理工商管理硕士学位，并在哈佛大学（Harvard University）获得神经生物学学士学位。
Vikas Goyal has served as our senior vice president, business development since August 2019. Prior to joining us, Mr. Goyal served as a principal of S.R. One, Limited, or S.R. One, the corporate venture capital arm of GlaxoSmithKline, from 2011 to July 2019. Mr. Goyal was a member of our board of directors from January 2018 to July 2019. Mr. Goyal is a member of the board of directors of Morphic Holding, Inc., a publicly traded biopharmaceuticals company. Mr. Goyal received an M.B.A. in health care management from the Wharton School of the University of Pennsylvania and a B.A. in neurobiology from Harvard University. - Vikas Goyal自2019年8月以来一直担任我们的高级副总裁，业务开发。在加入我们之前，Goyal先生于2011年至2019年7月担任葛兰素史克公司风险投资部门S.R.One，Limited或S.R.One的负责人。Goyal先生于2018年1月至2019年7月担任我们的董事会成员。Goyal先生是MorphicHolding，Inc.公司（一家公开上市的生物制药公司）董事会成员。Goyal先生在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得医疗保健管理工商管理硕士学位，并在哈佛大学（Harvard University）获得神经生物学学士学位。
- Vikas Goyal has served as our senior vice president, business development since August 2019. Prior to joining us, Mr. Goyal served as a principal of S.R. One, Limited, or S.R. One, the corporate venture capital arm of GlaxoSmithKline, from 2011 to July 2019. Mr. Goyal was a member of our board of directors from January 2018 to July 2019. Mr. Goyal is a member of the board of directors of Morphic Holding, Inc., a publicly traded biopharmaceuticals company. Mr. Goyal received an M.B.A. in health care management from the Wharton School of the University of Pennsylvania and a B.A. in neurobiology from Harvard University.
- Otello Stampacchia
-
Otello Stampacchia自2020年12月以来一直担任我们的董事会成员。Stampacchia博士是Omega Funds的创始人、董事总经理和投资委员会成员。Stampacchia博士目前在KronosBio，Inc.公司董事会任职。纳斯达克市场代码:KRON、MorphicHolding，Inc.（纳斯达克市场代码:MORF）和ReplimuneGroup，Inc.（纳斯达克市场代码:REPL），以及私营公司:Amunix Pharmaceuticals，Inc.和Scorpion Therapeutics，Inc.。在2004年1月创立Omega之前，Stampacchia博士是Alpinvest Partners（现在是凯雷集团的一部分）的合伙人。任职Alpinvest Partners公司之前，他曾担任Lombard Odier Immunology Fund（投资工具，位于瑞士日内瓦，投资于世界各地的公共和私营梦百合公司）的投资组合经理。此前，Stampacchia博士是高盛（Goldman Sachs）梦百合企业融资与并购团队的成员。在高盛之前，他帮助联合创立了Index Securities（现在的Index Ventures）梦百合投资活动。Stampacchia博士在帕维亚大学（University of Pavia）获得植物遗传学理学硕士学位，在日内瓦大学（University of Geneva）获得分子生物学理学硕士学位和分子生物学哲学博士学位，在欧洲联盟斯特拉斯堡（European Union Strasbourg）获得生物技术哲学博士学位。
Otello Stampacchia has served as a member of Board since July 2025. Dr. Stampacchia previoly served on the board of directors of Ikena from December 2020 to July 2025. Dr. Stampacchia is founder, managing director and member of the investment committee at Omega Fund Management, LLC. Dr. Stampacchia currently serves on the boards of directors of several private companies. Dr. Stampacchia previoly served on the board of directors of Kronos Bio, Inc. (Nasdaq: KRON), Median Technologies, Inc., Nuvation Bio, Inc. (NYSE: NUVB) and Replimune Group, Inc. (Nasdaq: REPL). Prior to founding Omega in January 2004, Dr. Stampacchia was a Partner at AlpInvest Partners (now part of The Carlyle Group). Before AlpInvest Partners, he was the portfolio manager of the Lombard Odier Immunology Fund, an investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previoly, Dr. Stampacchia was a member of the HealthCare corporate finance and M&A team at Goldman Sachs. Before Goldman Sachs, he helped co found the healthcare investment activities at Index Securities (now Index Ventures). Dr. Stampacchia received a Masters of Science in Plant Genetics from the University of Pavia, a Masters of Science in Molecular Biology, a Doctorate of Philosophy in Molecular Biology from the University of Geneva and a Doctorate of Philosophy in Biotechnology from European Union Strasbg. - Otello Stampacchia自2020年12月以来一直担任我们的董事会成员。Stampacchia博士是Omega Funds的创始人、董事总经理和投资委员会成员。Stampacchia博士目前在KronosBio，Inc.公司董事会任职。纳斯达克市场代码:KRON、MorphicHolding，Inc.（纳斯达克市场代码:MORF）和ReplimuneGroup，Inc.（纳斯达克市场代码:REPL），以及私营公司:Amunix Pharmaceuticals，Inc.和Scorpion Therapeutics，Inc.。在2004年1月创立Omega之前，Stampacchia博士是Alpinvest Partners（现在是凯雷集团的一部分）的合伙人。任职Alpinvest Partners公司之前，他曾担任Lombard Odier Immunology Fund（投资工具，位于瑞士日内瓦，投资于世界各地的公共和私营梦百合公司）的投资组合经理。此前，Stampacchia博士是高盛（Goldman Sachs）梦百合企业融资与并购团队的成员。在高盛之前，他帮助联合创立了Index Securities（现在的Index Ventures）梦百合投资活动。Stampacchia博士在帕维亚大学（University of Pavia）获得植物遗传学理学硕士学位，在日内瓦大学（University of Geneva）获得分子生物学理学硕士学位和分子生物学哲学博士学位，在欧洲联盟斯特拉斯堡（European Union Strasbourg）获得生物技术哲学博士学位。
- Otello Stampacchia has served as a member of Board since July 2025. Dr. Stampacchia previoly served on the board of directors of Ikena from December 2020 to July 2025. Dr. Stampacchia is founder, managing director and member of the investment committee at Omega Fund Management, LLC. Dr. Stampacchia currently serves on the boards of directors of several private companies. Dr. Stampacchia previoly served on the board of directors of Kronos Bio, Inc. (Nasdaq: KRON), Median Technologies, Inc., Nuvation Bio, Inc. (NYSE: NUVB) and Replimune Group, Inc. (Nasdaq: REPL). Prior to founding Omega in January 2004, Dr. Stampacchia was a Partner at AlpInvest Partners (now part of The Carlyle Group). Before AlpInvest Partners, he was the portfolio manager of the Lombard Odier Immunology Fund, an investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previoly, Dr. Stampacchia was a member of the HealthCare corporate finance and M&A team at Goldman Sachs. Before Goldman Sachs, he helped co found the healthcare investment activities at Index Securities (now Index Ventures). Dr. Stampacchia received a Masters of Science in Plant Genetics from the University of Pavia, a Masters of Science in Molecular Biology, a Doctorate of Philosophy in Molecular Biology from the University of Geneva and a Doctorate of Philosophy in Biotechnology from European Union Strasbg.
- Nilesh Kumar
-
Nilesh Kumar自2020年6月以来一直担任我们的董事会成员。Kumar博士自2017年1月起担任Novo Ventures US，Inc.的合伙人，该公司为丹麦私人有限责任公司Novo Holdings A/S提供咨询服务，在此之前，自2015年4月起担任高级负责人。任职Novo Ventures公司之前，他曾担任Merck KGaA公司家族的多种职务（2009年以来），最终担任高级投资董事，在那里他曾领导肿瘤和自身免疫性疾病领域的风险投资和战略许可交易。Kumar博士还担任生物制药公司MorphicHolding，Inc.和几家私营公司的董事会成员。Kumar博士拥有剑桥大学（Cambridge University）自然科学学士学位，哈佛大学（Harvard University）化学博士学位和哈佛商学院（Harvard Business School）工商管理硕士学位。
Nilesh Kumar has served as a member of our board of directors since June 2020. Dr. Kumar has been employed as a partner at Novo Ventures US, Inc., which provides consulting services to Novo Holdings A/S, a Danish private limited liability company, since January 2017 and before that, a Senior Principal since April 2015. Prior to Novo Ventures, he held various positions in the Merck KGaA family of companies since 2009 culminating in the position of Senior Investment Director, where he led venture investments and strategic licensing transactions in the field of oncology and autoimmune diseases. Dr. Kumar also serves on the board of directors of Morphic Holding, Inc., a biopharmaceutical company, and of several private companies. Dr. Kumar holds a B.A. in Natural Sciences from Cambridge University, a Ph.D. in Chemistry from Harvard University and an M.B.A. from Harvard Business School. - Nilesh Kumar自2020年6月以来一直担任我们的董事会成员。Kumar博士自2017年1月起担任Novo Ventures US，Inc.的合伙人，该公司为丹麦私人有限责任公司Novo Holdings A/S提供咨询服务，在此之前，自2015年4月起担任高级负责人。任职Novo Ventures公司之前，他曾担任Merck KGaA公司家族的多种职务（2009年以来），最终担任高级投资董事，在那里他曾领导肿瘤和自身免疫性疾病领域的风险投资和战略许可交易。Kumar博士还担任生物制药公司MorphicHolding，Inc.和几家私营公司的董事会成员。Kumar博士拥有剑桥大学（Cambridge University）自然科学学士学位，哈佛大学（Harvard University）化学博士学位和哈佛商学院（Harvard Business School）工商管理硕士学位。
- Nilesh Kumar has served as a member of our board of directors since June 2020. Dr. Kumar has been employed as a partner at Novo Ventures US, Inc., which provides consulting services to Novo Holdings A/S, a Danish private limited liability company, since January 2017 and before that, a Senior Principal since April 2015. Prior to Novo Ventures, he held various positions in the Merck KGaA family of companies since 2009 culminating in the position of Senior Investment Director, where he led venture investments and strategic licensing transactions in the field of oncology and autoimmune diseases. Dr. Kumar also serves on the board of directors of Morphic Holding, Inc., a biopharmaceutical company, and of several private companies. Dr. Kumar holds a B.A. in Natural Sciences from Cambridge University, a Ph.D. in Chemistry from Harvard University and an M.B.A. from Harvard Business School.
- Barbara J. Dalton
-
BarbaraJ.Dalton自2016年6月以来一直担任我们的董事会成员。自2007年9月以来，Dalton博士一直担任辉瑞风险投资公司（Pfizer Ventures）的Vice President、WWBD和高级管理合伙人。辉瑞风险投资公司是辉瑞公司的风险投资部门此前，Dalton博士曾担任EuclidSR Partners LP的合伙人和SR One的总裁。Dalton博士在宾夕法尼亚州立大学（Penn State）获得普通科学学士学位，并在德雷克塞尔大学医学院（Drexel University College of Medicine）获得微生物学和免疫学博士学位。
Barbara J. Dalton has served as a member of our board of directors since June 2016. Since September 2007 Dr. Dalton has served as Vice President, WWBD and Senior Managing Partner of Pfizer Ventures, the venture capital arm of Pfizer Inc. Previously, Dr. Dalton served as Partner at EuclidSR Partners LP and President at SR One. Dr. Dalton earned a B.S. in General Science from Penn State and a Ph.D. in Microbiology and Immunology from Drexel University College of Medicine. - BarbaraJ.Dalton自2016年6月以来一直担任我们的董事会成员。自2007年9月以来，Dalton博士一直担任辉瑞风险投资公司（Pfizer Ventures）的Vice President、WWBD和高级管理合伙人。辉瑞风险投资公司是辉瑞公司的风险投资部门此前，Dalton博士曾担任EuclidSR Partners LP的合伙人和SR One的总裁。Dalton博士在宾夕法尼亚州立大学（Penn State）获得普通科学学士学位，并在德雷克塞尔大学医学院（Drexel University College of Medicine）获得微生物学和免疫学博士学位。
- Barbara J. Dalton has served as a member of our board of directors since June 2016. Since September 2007 Dr. Dalton has served as Vice President, WWBD and Senior Managing Partner of Pfizer Ventures, the venture capital arm of Pfizer Inc. Previously, Dr. Dalton served as Partner at EuclidSR Partners LP and President at SR One. Dr. Dalton earned a B.S. in General Science from Penn State and a Ph.D. in Microbiology and Immunology from Drexel University College of Medicine.
- Praveen P. Tipirneni
-
自2015年7月以来，PraveenP.Tipirneni一直担任我们的总裁兼首席执行官以及董事会成员。此前，他曾于2002年11月至2015年2月担任专注于抗生素的生物技术公司CubistPharmaceuticals，Inc.的企业发展和全球战略高级副总裁。在Cubist Pharmaceuticals之前，Tipirneni博士还在Sun Microsystems，Inc.，Covad Communications Group和Deltagen，Inc.担任管理职位。Tipirneni博士在麻省理工学院（Massachusetts Institute of Technology）获得机械工程学士学位，在麦吉尔大学（McGill University）获得医学博士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
Praveen P. Tipirneni has served as our President and Chief Executive Officer and a member of our board of directors since July 2015. Previously, he served as the Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals, Inc., a biotechnology company focused on antibiotics, from November 2002 to February 2015. Prior to Cubist Pharmaceuticals, Dr. Tipirneni also held management positions at Sun Microsystems, Inc., Covad Communications Group and Deltagen, Inc. Dr. Tipirneni received a B.A. in Mechanical Engineering from Massachusetts Institute of Technology, an M.D. from McGill University and an M.B.A. from the Wharton School of Business of the University of Pennsylvania. - 自2015年7月以来，PraveenP.Tipirneni一直担任我们的总裁兼首席执行官以及董事会成员。此前，他曾于2002年11月至2015年2月担任专注于抗生素的生物技术公司CubistPharmaceuticals，Inc.的企业发展和全球战略高级副总裁。在Cubist Pharmaceuticals之前，Tipirneni博士还在Sun Microsystems，Inc.，Covad Communications Group和Deltagen，Inc.担任管理职位。Tipirneni博士在麻省理工学院（Massachusetts Institute of Technology）获得机械工程学士学位，在麦吉尔大学（McGill University）获得医学博士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
- Praveen P. Tipirneni has served as our President and Chief Executive Officer and a member of our board of directors since July 2015. Previously, he served as the Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals, Inc., a biotechnology company focused on antibiotics, from November 2002 to February 2015. Prior to Cubist Pharmaceuticals, Dr. Tipirneni also held management positions at Sun Microsystems, Inc., Covad Communications Group and Deltagen, Inc. Dr. Tipirneni received a B.A. in Mechanical Engineering from Massachusetts Institute of Technology, an M.D. from McGill University and an M.B.A. from the Wharton School of Business of the University of Pennsylvania.
- Norbert Bischofberger
-
Norbert Bischofberger自2018年8月起担任我们的总裁兼首席执行官，自2018年4月起担任我们的董事会成员，并于2020年7月至2020年8月担任我们的代理首席财务官。1990年8月至2018年8月，Bischofberger博士曾在生物制药公司吉利德科学公司担任多个职位，最近担任吉利德执行Vice President，研究与开发和首席科学官。任职Gilead公司28年期间，他曾主持超过25种治疗一系列严重疾病的疗法产品的开发和批准。在加入Gilead之前，Bischofberger博士从1986年到1990年担任生物技术公司Genentech，Inc.DNA合成组的高级科学家。Bischofberger博士在拜耳公司（Bayer AG）的监事会和Morphic Therapeutic公司（一家公共生物制药公司）的董事会任职。Bischofberger博士在瑞士苏黎世的Eidgenosische Technische Hochschule获得有机化学博士学位，并在因斯布鲁克大学（University of Innsbruck）获得化学硕士学位。
Norbert Bischofberger has served as our President and Chief Executive Officer since August 2018 as a member of our board of directors since April 2018 and as our acting principal financial officer from July 2020 to August 2020. From August 1990 to August 2018 Dr. Bischofberger held various positions at Gilead Sciences, Inc., a biopharmaceutical company, and most recently served Gilead as Executive Vice President, Research and Development and Chief Scientific Officer. During his 28-year tenure at Gilead, he presided over the development and approval of more than 25 therapeutics products for a range of serious conditions. Prior to Gilead, Dr. Bischofberger served as a Senior Scientist in the DNA Synthesis group at Genentech, Inc., a biotechnology company, from 1986 to 1990. Dr. Bischofberger serves on the Supervisory Board of Bayer AG and board of directors of Morphic Therapeutic, a public biopharmaceutical company. Dr. Bischofberger received a Ph.D. in Organic Chemistry from the Eidgenossische Technische Hochschule in Zurich, Switzerland and an M.S. in Chemistry from the University of Innsbruck. - Norbert Bischofberger自2018年8月起担任我们的总裁兼首席执行官，自2018年4月起担任我们的董事会成员，并于2020年7月至2020年8月担任我们的代理首席财务官。1990年8月至2018年8月，Bischofberger博士曾在生物制药公司吉利德科学公司担任多个职位，最近担任吉利德执行Vice President，研究与开发和首席科学官。任职Gilead公司28年期间，他曾主持超过25种治疗一系列严重疾病的疗法产品的开发和批准。在加入Gilead之前，Bischofberger博士从1986年到1990年担任生物技术公司Genentech，Inc.DNA合成组的高级科学家。Bischofberger博士在拜耳公司（Bayer AG）的监事会和Morphic Therapeutic公司（一家公共生物制药公司）的董事会任职。Bischofberger博士在瑞士苏黎世的Eidgenosische Technische Hochschule获得有机化学博士学位，并在因斯布鲁克大学（University of Innsbruck）获得化学硕士学位。
- Norbert Bischofberger has served as our President and Chief Executive Officer since August 2018 as a member of our board of directors since April 2018 and as our acting principal financial officer from July 2020 to August 2020. From August 1990 to August 2018 Dr. Bischofberger held various positions at Gilead Sciences, Inc., a biopharmaceutical company, and most recently served Gilead as Executive Vice President, Research and Development and Chief Scientific Officer. During his 28-year tenure at Gilead, he presided over the development and approval of more than 25 therapeutics products for a range of serious conditions. Prior to Gilead, Dr. Bischofberger served as a Senior Scientist in the DNA Synthesis group at Genentech, Inc., a biotechnology company, from 1986 to 1990. Dr. Bischofberger serves on the Supervisory Board of Bayer AG and board of directors of Morphic Therapeutic, a public biopharmaceutical company. Dr. Bischofberger received a Ph.D. in Organic Chemistry from the Eidgenossische Technische Hochschule in Zurich, Switzerland and an M.S. in Chemistry from the University of Innsbruck.
- Gustav Christensen
-
Gustav Christensen， 自2009年起成为 Dyax总裁、首席执行官和董事。从2007年4月到2008年12月担任Dyax执行副总裁和首席商务官，负责监管公司战略合作以及其他业务开发活动，如许可和合作交易。之前曾从2005年到2007年担任Apeiron合伙有限责任公司（一家精装生命科学投资银行）管理董事。他在 Baxter Travenol实验室担任总经理开始自己的职业生涯，之后成为Genetics Institute有限公司业务发展副总裁。此外，他还担任多个生物制药公司首席执行官和高级管理人。他持有丹麦的奥胡斯大学经济学理学学士学位以及哈佛商学院工商管理硕士学位。
Gustav Christensen has served as a member of our board of directors since December 2017. Mr. Christensen has served as the chairman of the board of directors of Morphic Holding, Inc., since April 2016. Previously, Mr. Christensen served as the president and chief executive officer and director at Dyax Corp., a biopharmaceutical company, from April 2007 to February 2016. Mr. Christensen earned a M.Sc. in Economics from the University of Aarhus Denmark and his M.B.A. from Harvard Business School. - Gustav Christensen， 自2009年起成为 Dyax总裁、首席执行官和董事。从2007年4月到2008年12月担任Dyax执行副总裁和首席商务官，负责监管公司战略合作以及其他业务开发活动，如许可和合作交易。之前曾从2005年到2007年担任Apeiron合伙有限责任公司（一家精装生命科学投资银行）管理董事。他在 Baxter Travenol实验室担任总经理开始自己的职业生涯，之后成为Genetics Institute有限公司业务发展副总裁。此外，他还担任多个生物制药公司首席执行官和高级管理人。他持有丹麦的奥胡斯大学经济学理学学士学位以及哈佛商学院工商管理硕士学位。
- Gustav Christensen has served as a member of our board of directors since December 2017. Mr. Christensen has served as the chairman of the board of directors of Morphic Holding, Inc., since April 2016. Previously, Mr. Christensen served as the president and chief executive officer and director at Dyax Corp., a biopharmaceutical company, from April 2007 to February 2016. Mr. Christensen earned a M.Sc. in Economics from the University of Aarhus Denmark and his M.B.A. from Harvard Business School.
- Joseph P. Slattery
-
Joseph P. Slattery自2019年5月起担任Morphic Holding, Inc.董事会成员。2013年10月以来，他担任TransEnterix, Inc.(医疗设备公司)的执行副总裁兼首席财务官。从2010年4月到2013年9月，他担任Baxano Surgical Inc.(一家微创脊柱手术公司)的执行副总裁兼首席财务官。从1996年2月到2007年8月，他担任财务和会计职务，包括Digene公司(一家分子诊断公司，于2007年被Qiagen, N.V.收购)的首席财务官和财务和信息系统高级副总裁。目前，他担任Replimune Group, Inc.和某些私人公司的董事会成员。他持有Bentley University的会计学士学位，是一名注册会计师。
Joseph P. Slattery has served as a member of Morphic Holding, Inc. board of directors since May 2019. Since October 2013 he has served as Executive Vice President and Chief Financial Officer of TransEnterix, Inc., a medical device company. Mr. Slattery served as Executive Vice President and Chief Financial Officer at Baxano Surgical Inc., a minimally invasive spinal surgery company, from April 2010 to September 2013. From February 1996 to August 2007 he served in finance and accounting roles including Chief Financial Officer and Senior Vice President of Finance and Information Systems of Digene Corp., a molecular diagnostics company acquired by Qiagen, N.V. in 2007. Currently, he serves on the boards of directors of Replimune Group, Inc. and certain private companies. Mr. Slattery earned a B.S. in Accounting from Bentley University and is a certified public accountant. - Joseph P. Slattery自2019年5月起担任Morphic Holding, Inc.董事会成员。2013年10月以来，他担任TransEnterix, Inc.(医疗设备公司)的执行副总裁兼首席财务官。从2010年4月到2013年9月，他担任Baxano Surgical Inc.(一家微创脊柱手术公司)的执行副总裁兼首席财务官。从1996年2月到2007年8月，他担任财务和会计职务，包括Digene公司(一家分子诊断公司，于2007年被Qiagen, N.V.收购)的首席财务官和财务和信息系统高级副总裁。目前，他担任Replimune Group, Inc.和某些私人公司的董事会成员。他持有Bentley University的会计学士学位，是一名注册会计师。
- Joseph P. Slattery has served as a member of Morphic Holding, Inc. board of directors since May 2019. Since October 2013 he has served as Executive Vice President and Chief Financial Officer of TransEnterix, Inc., a medical device company. Mr. Slattery served as Executive Vice President and Chief Financial Officer at Baxano Surgical Inc., a minimally invasive spinal surgery company, from April 2010 to September 2013. From February 1996 to August 2007 he served in finance and accounting roles including Chief Financial Officer and Senior Vice President of Finance and Information Systems of Digene Corp., a molecular diagnostics company acquired by Qiagen, N.V. in 2007. Currently, he serves on the boards of directors of Replimune Group, Inc. and certain private companies. Mr. Slattery earned a B.S. in Accounting from Bentley University and is a certified public accountant.
- Amir Nashat
-
Amir Nashat, Sc.D.，2008年2月成为Scholar Rock Holding Corporation的董事会成员。自2009年以来，他是Polaris Venture Partners公司（一个风险投资公司）一般合伙人，专注于生命科学投资。他目前是Receptos有限公司董事会和Fate Therapeutics公司董事会成员。他在麻省理工学院的化学工程完成了他的科学博士学位，在Langer博士的指导下辅修生物学。他持有加州大学，伯克利分校材料科学与机械工程硕士和博士学位。
Amir Nashat,has served as a member of Board since 2015. Dr. Nashat is an executive partner at Polaris Partners, a venture capital firm, where he has worked since 2002. Dr. Nashat currently represents Polaris on the board of directors of Morphic Holding, Inc., a biopharmaceutical company developing small molecule integrin therapeutics, where he has served since 2017. Dr. Nashat previously served as a member of the boards of directors of Scholar Rock Holding Corporation from 2012 to June 2024, of Fate Therapeutics, Inc., from 2007 to May 2020, of Selecta Biosciences, Inc., from 2008 to April 2020, and of Syros Pharmaceuticals, Inc., from 2016 to September 2022. Prior to joining Polaris, Dr. Nashat completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology. Dr. Nashat also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley. - Amir Nashat, Sc.D.，2008年2月成为Scholar Rock Holding Corporation的董事会成员。自2009年以来，他是Polaris Venture Partners公司（一个风险投资公司）一般合伙人，专注于生命科学投资。他目前是Receptos有限公司董事会和Fate Therapeutics公司董事会成员。他在麻省理工学院的化学工程完成了他的科学博士学位，在Langer博士的指导下辅修生物学。他持有加州大学，伯克利分校材料科学与机械工程硕士和博士学位。
- Amir Nashat,has served as a member of Board since 2015. Dr. Nashat is an executive partner at Polaris Partners, a venture capital firm, where he has worked since 2002. Dr. Nashat currently represents Polaris on the board of directors of Morphic Holding, Inc., a biopharmaceutical company developing small molecule integrin therapeutics, where he has served since 2017. Dr. Nashat previously served as a member of the boards of directors of Scholar Rock Holding Corporation from 2012 to June 2024, of Fate Therapeutics, Inc., from 2007 to May 2020, of Selecta Biosciences, Inc., from 2008 to April 2020, and of Syros Pharmaceuticals, Inc., from 2016 to September 2022. Prior to joining Polaris, Dr. Nashat completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology. Dr. Nashat also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.
- Barbara J. Dalton
-
Barbara J. Dalton， 2012年1月至2013年10月，她曾担任我们的董事会成员和董事会主席。自2007年7月起，她曾担任辉瑞风险投资公司的副总裁，在那里她负责辉瑞风险投资投资——专注于私募股权投资的辉瑞制药投资部门。2000年1月至2007年6月，她担任EuclidSR合伙公司的普通合伙人，这是一家私人风险投资公司，在那里她是一个创始成员。1983年她开始了她的职业生涯，1993年至2003年在移到她们自己的创投子公司——SR One有限公司之前，担任SmithKline公司（一家制药公司）的研究科学家。她领导纽约市投资基金的医疗保健投资集团，是阿尔茨海默氏症研究基金会和美国国家风险投资协会的董事会前成员。她是宾夕法尼亚州立大学埃伯利科学学院的院长顾问，在那里她获得了她的本科学位，以及宾州州立大学研究基金会的董事会成员。她获得宾夕法尼亚医学院（现在医学德雷克塞尔大学学院的一部分）免疫学与微生物的博士学位。
Barbara J. Dalton has served as a member of our board of directors since January 2016. Dr. Dalton is the Vice President of Venture Capital for Pfizer Ventures, the venture capital group of Pfizer Inc. and, with its affiliates, a holder of more than 5 of our voting securities, since she joined Pfizer in 2007. She serves on the board of Artios Ltd., Complexa Inc., Cydan, Ixchelsis Ltd, Petra Pharma Corporation, and System1 Biosciences, Inc., which are all private independent biopharmaceutical companies. Barbara also serves on several other Pfizer Venture Investments portfolio companies as a board observer. Dr. Dalton began her pharmaceutical career as a Research Scientist in Immunology at SmithKline Beecham Ltd. formerly SmithKline and French Laboratories, a pharmaceutical company that merged with Glaxo Holdings to become GSK, and joined their venture capital group, SR One, Ltd., in the early 1990s. She was also a founding member and Partner with EuclidSR Partners LP, a private venture capital firm, where SmithKline was a leading limited partner. She received her Ph.D. in microbiology and immunology from The Medical College of Pennsylvania (now the Drexel University College of Medicine) and received her B.S. in General Science from Pennsylvania State University. - Barbara J. Dalton， 2012年1月至2013年10月，她曾担任我们的董事会成员和董事会主席。自2007年7月起，她曾担任辉瑞风险投资公司的副总裁，在那里她负责辉瑞风险投资投资——专注于私募股权投资的辉瑞制药投资部门。2000年1月至2007年6月，她担任EuclidSR合伙公司的普通合伙人，这是一家私人风险投资公司，在那里她是一个创始成员。1983年她开始了她的职业生涯，1993年至2003年在移到她们自己的创投子公司——SR One有限公司之前，担任SmithKline公司（一家制药公司）的研究科学家。她领导纽约市投资基金的医疗保健投资集团，是阿尔茨海默氏症研究基金会和美国国家风险投资协会的董事会前成员。她是宾夕法尼亚州立大学埃伯利科学学院的院长顾问，在那里她获得了她的本科学位，以及宾州州立大学研究基金会的董事会成员。她获得宾夕法尼亚医学院（现在医学德雷克塞尔大学学院的一部分）免疫学与微生物的博士学位。
- Barbara J. Dalton has served as a member of our board of directors since January 2016. Dr. Dalton is the Vice President of Venture Capital for Pfizer Ventures, the venture capital group of Pfizer Inc. and, with its affiliates, a holder of more than 5 of our voting securities, since she joined Pfizer in 2007. She serves on the board of Artios Ltd., Complexa Inc., Cydan, Ixchelsis Ltd, Petra Pharma Corporation, and System1 Biosciences, Inc., which are all private independent biopharmaceutical companies. Barbara also serves on several other Pfizer Venture Investments portfolio companies as a board observer. Dr. Dalton began her pharmaceutical career as a Research Scientist in Immunology at SmithKline Beecham Ltd. formerly SmithKline and French Laboratories, a pharmaceutical company that merged with Glaxo Holdings to become GSK, and joined their venture capital group, SR One, Ltd., in the early 1990s. She was also a founding member and Partner with EuclidSR Partners LP, a private venture capital firm, where SmithKline was a leading limited partner. She received her Ph.D. in microbiology and immunology from The Medical College of Pennsylvania (now the Drexel University College of Medicine) and received her B.S. in General Science from Pennsylvania State University.
高管简历
中英对照 | 中文 | 英文- Robert E. Farrell
自2015年6月以来，RobertE.Farrell一直担任我们的财务和运营Vice President兼财务主管。从2015年3月到2015年6月，Farrell先生担任独立顾问。2009年4月至2015年3月，Farrell先生担任Genocea Biosciences Inc.的财务和行政Vice President兼财务主管。此前，Farrell先生曾在Oscient Pharmaceuticals Corp.，Magen Biosciences，Inc.和Neogenesis Pharmaceuticals，Inc.担任多个高级财务职位。Farrell先生在宾利大学（Bentley University）获得会计学学士学位。
Robert E. Farrell has served as our Vice President of Finance and Operations and Treasurer since June 2015. From March 2015 to June 2015 Mr. Farrell worked as an independent consultant. From April 2009 to March 2015 Mr. Farrell served as Vice President of Finance and Administration and Treasurer of Genocea Biosciences Inc. Previously, Mr. Farrell served in various senior level financial positions at Oscient Pharmaceuticals Corp., Magen Biosciences, Inc. and NeoGenesis Pharmaceuticals, Inc. Mr. Farrell received a B.S. in Accounting from Bentley University.- 自2015年6月以来，RobertE.Farrell一直担任我们的财务和运营Vice President兼财务主管。从2015年3月到2015年6月，Farrell先生担任独立顾问。2009年4月至2015年3月，Farrell先生担任Genocea Biosciences Inc.的财务和行政Vice President兼财务主管。此前，Farrell先生曾在Oscient Pharmaceuticals Corp.，Magen Biosciences，Inc.和Neogenesis Pharmaceuticals，Inc.担任多个高级财务职位。Farrell先生在宾利大学（Bentley University）获得会计学学士学位。
- Robert E. Farrell has served as our Vice President of Finance and Operations and Treasurer since June 2015. From March 2015 to June 2015 Mr. Farrell worked as an independent consultant. From April 2009 to March 2015 Mr. Farrell served as Vice President of Finance and Administration and Treasurer of Genocea Biosciences Inc. Previously, Mr. Farrell served in various senior level financial positions at Oscient Pharmaceuticals Corp., Magen Biosciences, Inc. and NeoGenesis Pharmaceuticals, Inc. Mr. Farrell received a B.S. in Accounting from Bentley University.
- William D. DeVaul
WilliamD.DeVaul自2019年2月起担任我们的总法律顾问兼秘书。2015年5月至2019年2月，他担任生物技术公司EveloBiosciences，Inc.知识产权主管Vice President。加入Evelo之前，Devaul从2003年12月到2015年2月担任Cubist Pharmaceuticals多个职位，包括最近担任副首席知识产权顾问。Devaul先生在波士顿大学法学院（Boston University School of Law）获得法学博士学位，并在哥伦比亚大学（Columbia University）获得生物化学学士学位。
William D. DeVaul has served as our General Counsel and Secretary since February 2019. From May 2015 to February 2019 he served as Vice President, Head of Intellectual Property at Evelo Biosciences, Inc., a biotechnology company. Prior to Evelo, Mr. DeVaul served Cubist Pharmaceuticals in various positions from December 2003 to February 2015 including most recently as Deputy Chief Intellectual Property Counsel. Mr. DeVaul earned a J.D. from Boston University School of Law and a B.A. in Biochemistry from Columbia University.- WilliamD.DeVaul自2019年2月起担任我们的总法律顾问兼秘书。2015年5月至2019年2月，他担任生物技术公司EveloBiosciences，Inc.知识产权主管Vice President。加入Evelo之前，Devaul从2003年12月到2015年2月担任Cubist Pharmaceuticals多个职位，包括最近担任副首席知识产权顾问。Devaul先生在波士顿大学法学院（Boston University School of Law）获得法学博士学位，并在哥伦比亚大学（Columbia University）获得生物化学学士学位。
- William D. DeVaul has served as our General Counsel and Secretary since February 2019. From May 2015 to February 2019 he served as Vice President, Head of Intellectual Property at Evelo Biosciences, Inc., a biotechnology company. Prior to Evelo, Mr. DeVaul served Cubist Pharmaceuticals in various positions from December 2003 to February 2015 including most recently as Deputy Chief Intellectual Property Counsel. Mr. DeVaul earned a J.D. from Boston University School of Law and a B.A. in Biochemistry from Columbia University.
- Bruce N. Rogers
BruceN.Rogers自2016年1月起担任我们的首席科学官。2014年6月至2016年1月，Rogers博士担任辉瑞公司的神经机会主管在担任该职位之前，Rogers博士从2003年8月开始在辉瑞全球研发（Pfizer Global R&D）的药物化学组织中担任越来越重要的职位。Rogers博士从1998年9月到2003年8月在Pharmacia&Upjohn Company LLC开始了他在私营部门的职业生涯，担任科学家。Rogers博士在明尼苏达大学（University of Minnesota）获得化学学士学位，在加州大学欧文分校（University of California at Irvine）获得有机化学博士学位，并在加州大学（University of California）获得国家卫生研究院博士后研究员。
Bruce N. Rogers has served as our Chief Scientific Officer since January 2016. From June 2014 to January 2016 Dr. Rogers served as the Head of Neuro-Opportunities at Pfizer Inc. Prior to that position, Dr. Rogers held positions of increasing responsibility within the medicinal chemistry organization at Pfizer Global R&D since August 2003. Dr. Rogers started his career in the private sector at Pharmacia & Upjohn Company LLC as a scientist from September 1998 to August 2003. Dr. Rogers received a B.A. in Chemistry from the University of Minnesota, a Ph.D. in Organic Chemistry from the University of California at Irvine and was a National Institutes of Health postdoctoral fellow at the University of California.- BruceN.Rogers自2016年1月起担任我们的首席科学官。2014年6月至2016年1月，Rogers博士担任辉瑞公司的神经机会主管在担任该职位之前，Rogers博士从2003年8月开始在辉瑞全球研发（Pfizer Global R&D）的药物化学组织中担任越来越重要的职位。Rogers博士从1998年9月到2003年8月在Pharmacia&Upjohn Company LLC开始了他在私营部门的职业生涯，担任科学家。Rogers博士在明尼苏达大学（University of Minnesota）获得化学学士学位，在加州大学欧文分校（University of California at Irvine）获得有机化学博士学位，并在加州大学（University of California）获得国家卫生研究院博士后研究员。
- Bruce N. Rogers has served as our Chief Scientific Officer since January 2016. From June 2014 to January 2016 Dr. Rogers served as the Head of Neuro-Opportunities at Pfizer Inc. Prior to that position, Dr. Rogers held positions of increasing responsibility within the medicinal chemistry organization at Pfizer Global R&D since August 2003. Dr. Rogers started his career in the private sector at Pharmacia & Upjohn Company LLC as a scientist from September 1998 to August 2003. Dr. Rogers received a B.A. in Chemistry from the University of Minnesota, a Ph.D. in Organic Chemistry from the University of California at Irvine and was a National Institutes of Health postdoctoral fellow at the University of California.
- Alexey A. Lugovskoy
AlexeyA.Lugovskoy自2016年1月起担任我们的首席开发官。此前，Lugovskoy博士曾于2010年6月至2016年1月担任生物制药公司MerrimackPharmaceuticals，Inc.Therapeutics的Vice President。在加入Merrimack之前，Lugovskoy博士从2001年9月到2010年6月担任BiogenInc.（一家生物技术公司）药物发现副总监。Lugovskoy博士自2013年12月起担任杂志MABS的助理编辑。Lugovskoy博士在麻省理工学院斯隆管理学院（MIT Sloan School of Management）获得管理、创新与技术高管高级证书，在哈佛大学（Harvard University）获得生物物理学博士学位和理学硕士学位。分子生物物理学和理学学士学位。在莫斯科物理和技术学院获得数学和物理学学士学位。
Alexey A. Lugovskoy has served as our Chief Development Officer since January 2016. Previously, Dr. Lugovskoy served as a Vice President of Therapeutics of Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, where he worked from June 2010 to January 2016. Prior to joining Merrimack, Dr. Lugovskoy served as Associate Director of Drug Discovery at Biogen Inc., a biotechnology company, where he worked from September 2001 to June 2010. Dr. Lugovskoy has been an Assistant Editor of the journal mAbs since December 2013. Dr. Lugovskoy received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University and a M.Sc. in Molecular Biophysics and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.- AlexeyA.Lugovskoy自2016年1月起担任我们的首席开发官。此前，Lugovskoy博士曾于2010年6月至2016年1月担任生物制药公司MerrimackPharmaceuticals，Inc.Therapeutics的Vice President。在加入Merrimack之前，Lugovskoy博士从2001年9月到2010年6月担任BiogenInc.（一家生物技术公司）药物发现副总监。Lugovskoy博士自2013年12月起担任杂志MABS的助理编辑。Lugovskoy博士在麻省理工学院斯隆管理学院（MIT Sloan School of Management）获得管理、创新与技术高管高级证书，在哈佛大学（Harvard University）获得生物物理学博士学位和理学硕士学位。分子生物物理学和理学学士学位。在莫斯科物理和技术学院获得数学和物理学学士学位。
- Alexey A. Lugovskoy has served as our Chief Development Officer since January 2016. Previously, Dr. Lugovskoy served as a Vice President of Therapeutics of Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, where he worked from June 2010 to January 2016. Prior to joining Merrimack, Dr. Lugovskoy served as Associate Director of Drug Discovery at Biogen Inc., a biotechnology company, where he worked from September 2001 to June 2010. Dr. Lugovskoy has been an Assistant Editor of the journal mAbs since December 2013. Dr. Lugovskoy received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University and a M.Sc. in Molecular Biophysics and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.
- Praveen P. Tipirneni
自2015年7月以来，PraveenP.Tipirneni一直担任我们的总裁兼首席执行官以及董事会成员。此前，他曾于2002年11月至2015年2月担任专注于抗生素的生物技术公司CubistPharmaceuticals，Inc.的企业发展和全球战略高级副总裁。在Cubist Pharmaceuticals之前，Tipirneni博士还在Sun Microsystems，Inc.，Covad Communications Group和Deltagen，Inc.担任管理职位。Tipirneni博士在麻省理工学院（Massachusetts Institute of Technology）获得机械工程学士学位，在麦吉尔大学（McGill University）获得医学博士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
Praveen P. Tipirneni has served as our President and Chief Executive Officer and a member of our board of directors since July 2015. Previously, he served as the Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals, Inc., a biotechnology company focused on antibiotics, from November 2002 to February 2015. Prior to Cubist Pharmaceuticals, Dr. Tipirneni also held management positions at Sun Microsystems, Inc., Covad Communications Group and Deltagen, Inc. Dr. Tipirneni received a B.A. in Mechanical Engineering from Massachusetts Institute of Technology, an M.D. from McGill University and an M.B.A. from the Wharton School of Business of the University of Pennsylvania.- 自2015年7月以来，PraveenP.Tipirneni一直担任我们的总裁兼首席执行官以及董事会成员。此前，他曾于2002年11月至2015年2月担任专注于抗生素的生物技术公司CubistPharmaceuticals，Inc.的企业发展和全球战略高级副总裁。在Cubist Pharmaceuticals之前，Tipirneni博士还在Sun Microsystems，Inc.，Covad Communications Group和Deltagen，Inc.担任管理职位。Tipirneni博士在麻省理工学院（Massachusetts Institute of Technology）获得机械工程学士学位，在麦吉尔大学（McGill University）获得医学博士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
- Praveen P. Tipirneni has served as our President and Chief Executive Officer and a member of our board of directors since July 2015. Previously, he served as the Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals, Inc., a biotechnology company focused on antibiotics, from November 2002 to February 2015. Prior to Cubist Pharmaceuticals, Dr. Tipirneni also held management positions at Sun Microsystems, Inc., Covad Communications Group and Deltagen, Inc. Dr. Tipirneni received a B.A. in Mechanical Engineering from Massachusetts Institute of Technology, an M.D. from McGill University and an M.B.A. from the Wharton School of Business of the University of Pennsylvania.